CIRM Funded Clinical Trials
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)
Disease Area:
COVID-19
Trial Sponsor:
University of California, San Francisco
Trial Stage:
Phase 2
Trial Status:
Completed
Targeted Enrollment:
120
ClinicalTrials.gov ID:
Details:
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs. As a result, breathing becomes difficult and oxygen cannot get into the body. ARDS is one of the most serious and lethal consequence of COVID-19.
This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.
Design:
Phase 2B trial
Goal:
Test safety and efficacy.
